Description
The range of frontline therapy options for mantle cell lymphoma can influence subsequent treatment choices for patients with relapsed or refractory disease. Providers must determine initial treatment based on individual patient characteristics, while also factoring in future treatment options. In this episode, CANCER BUZZ speaks with Nirav Shah, MD, MSHP, associate professor of medicine at Medical College of Wisconsin and Kirollos Hanna, PharmD, BCOP, PCOP, FACCC, assistant professor of pharmacy at Mayo Clinic and director of pharmacy at Minnesota Oncology, about shared decision making in the management of relapsed or refractory mantle cell lymphoma.
“The key to all of this is good collaboration between the community and their affiliates… their partners and academics, or tertiary referral centers, to really engage… these patients in a collaborative format… it really takes a team, a village, to take care of complex mantle cell lymphoma patients. “ –Dr. Nirav Shah, MD, MSHP
“We’re not really seeing a lot of CAR T-cell therapy move in the frontline setting just yet, while there are a lot of ongoing clinical trials… Really, right now, it’s going to be the patient characteristic: how well they did on frontline therapy, access to care, affordability, institutional preparedness… that would potentially… allow your patient to receive CAR T-cell therapy.” –Kirollos Hanna, PharmD, BCPS, PCOP, FACCC
Nirav Shah, MD, MSHP
Associate Professor of Medicine
Medical College of Wisconsin
Division of Hematology and Oncology
Milwaukee, Wisconsin
Kirollos Hanna, PharmD, BCPS, PCOP, FACCC
Assistant Professor of Pharmacy, Mayo Clinic
Director of Pharmacy
Minnesota Oncology
St. Paul, Minnesota
This project is made possible by funding and support provided by Eli Lilly and in collaboration with The Leukemia & Lymphoma Society.
Resources
Treatment for Relapsed/Refractory Mantle Cell Lymphoma Tip Sheet - ACCC
Relapsed/Refractory Mantle Cell Lymphoma Educational Video Series:
Update on New Therapies: https://vimeo.com/942756449
BTK Inhibitors in MCL: https://vimeo.com/942755401
R/R MCL Case Studies: https://vimeo.com/942754652
BTK Inhibitors Stretch Frontline Approaches in Mantle Cell Lymphoma – Targeted Oncology
Emerging Data Continue to Affect BTK Inhibitor Usage in Mantle Cell Lymphoma - OncLive
HCP Fact Sheet: Facts About CAR T-cell Therapy - https://www.lls.org/sites/default/files/2023-10/FSHP1_CART_Factsheet_June2022_rev.pdf
The CAR T-cell Therapy Process - https://www.lls.org/sites/default/files/2024-03/PS100_CART-CellTherapyProcessFlyer_0224.pdf
Patient-Caregiver CAR T-cell Therapy Facts - https://www.lls.org/sites/default/files/2024-04/FS27_CART_Fact_Sheet_0424_rev.pdf
Learn About CAR T-cell Therapy - https://www.lls.org/sites/default/files/2024-03/PS126_CART_ResourceCard_3_24.pdf
Mantle Cell Lymphoma Facts for Patients and Caregivers -The Leukemia & Lymphoma Society https://lls.org/sites/default/files/2023-08/FS4_Mantle_Cell_Facts_0423rev.pdf
Advancements in treatment combined with a multimodal approach are improving outcomes for patients with head and neck cancer. However, the unique challenges of a head and neck cancer diagnosis and its treatment side effects—such as speech and communication difficulties as well as negative effects...
Published 09/12/24
Female sexual dysfunction is a well-studied adverse effect of cancer treatment. Despite its prevalence, however, it remains vastly underdiagnosed and undertreated in oncology patients, with providers inadequately addressing sexual function before, during, and after treatment. Although most...
Published 08/29/24